Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
Top 10 Correlated ETFs
In the News
The Three Best Anti-Aging Stocks to Buy in September
Anti-aging stocks have not proven immune to poor market conditions that have plagued the broader biotech industry. The biotech industry remains hampered by the same bleak economic conditions as those affecting growth companies.
UNITY Biotechnology to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will participate in the following investor conferences in September.
Bears are Losing Control Over UNITY Biotechnology, Inc. (UBX), Here's Why It's a 'Buy' Now
UNITY Biotechnology, Inc. (UBX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Hot Penny Stocks to Add to Your Watchlist Right Now
Here's what you need to know about trading penny stocks on August 15th The post Hot Penny Stocks to Add to Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is Unity Biotechnology (UBX) Stock Up 71% Today?
Source: everything possible / Shutterstock.com Unity Biotechnology (NASDAQ: UBX ) stock is surging higher on Friday following the release of its earnings report for the second quarter of 2022. That report starts with the company's current cash position sitting at $64.5 million.
Unity Biotechnology (UBX) Stock: Why It Skyrocketed Over 120% Today
The stock price of Unity Biotechnology (UBX) skyrocketed over 120% pre-market today. This is why.
UNITY Biotechnology to Present Clinical Data at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting
SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that 24-week clinical data results from the Phase 1 study of its lead senolytic candidate, UBX1325, in patients with diabetic macular edema and wet age-related macular degeneration will be presented at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting 2022, being held July 13-16, 2022. Details of the presentations are as follows:
Why Did Mizuho Upgrade This Biotech Stock Focused On Age-Related Eye Diseases?
Mizuho upgraded Unity Biotechnology Inc (NASDAQ: UBX) to Buy from Neutral with a price target of $7, up from $5 after Unity announced longer-term Phase 1 data for UBX1325 in diabetic macular edema (DME) and wet age-related macular degeneration (AMD). Analyst Salim Syed expects some investor sentiment shift to begin at this point for this "underfollowed" stock.
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from September 21, 2021, through October 5, 2021, the Compensation Committee of the Board of Directors (the “Board”) granted 4 new employees stock-based awards covering an aggregate of 138,500 shares of UNITY common stock, including options to purchase an aggregate of 138,500 shares of UNITY common stock. The stock-based awards were granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with UNITY in accordance with Nasdaq Stock Market Rule 5635(c)(4).
Unity Biotechnology Stock Falls After Updated Data From Wet AMD Candidate
Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and wet age-related macular degeneration (AMD), for whom anti-VEGF therapy was no longer considered beneficial. The data show strong and sustained responses following a single injection of UBX1325.
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
|Revenue per share||0||0||0||0|
|Net income per share||-2.7||-1.88||-1.84||0|
|Operating cash flow per share||-2||-1.66||-1.54||0|
|Free cash flow per share||-2.05||-1.7||-1.55||0|
|Cash per share||6.05||2.92||1.92||0.59|
|Book value per share||5.68||2.77||1.63||1.07|
|Tangible book value per share||5.68||2.77||1.63||1.07|
|Share holders equity per share||5.68||2.77||1.63||1.07|
|Interest debt per share||0||0||0.6||0.92|
|Price to sales ratio||0||0||0||12.72K|
|EV to sales||0||0||0||16.62K|
|Enterprise value over EBITDA||-4.23||-2.58||-3.48||-1.24K|
|EV to operating cash flow||-5.43||-3.15||-4.02||0|
|EV to free cash flow||-5.32||-3.08||-3.99||0|
|Free cash flow yield||-0.18||-0.28||-0.26||0|
|Debt to equity||0||0||0.3||0.81|
|Debt to assets||0.11||0.2||0.47||0.52|
|Net debt to EBITDA||0.21||0.42||-0.12||-291.9|
|Sales general and administrative to revenue||0||0||0||4.82|
|Research and developement to revenue||0||0||0||8.03|
|Intangibles to total assets||0||0||0||0|
|Capex to operating cash flow||0.02||0.02||0.01||0|
|Capex to revenue||0||0||0||0|
|Capex to depreciation||-0.58||-0.6||-0.19||0|
|Stock based compensation to revenue||0||0||0||0|
|Return on tangible assets||-0.42||-0.54||-0.6||0|
|Tangible asset value||0||0||0||0|
|Net current asset value||152.28M||98.97M||27.43M||25.36M|
|Days sales outstanding||0||0||0||0|
|Days payables outstanding||0||0||0||0|
|Days of inventory on hand||0||0||0||0|
|Capex per share||-0.04||-0.04||-0.01||0|
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
|Revenue per share||0||0||0||0||0|
|Net income per share||-0.32||-0.3||0||-0.28||-0.19|
|Operating cash flow per share||-0.24||-0.21||0||-0.22||-0.21|
|Free cash flow per share||-0.25||-0.21||0||-0.22||-0.21|
|Cash per share||1.53||1.46||0.56||1.17||0.93|
|Book value per share||1.2||1.04||1.01||0.75||0.58|
|Tangible book value per share||1.2||1.04||1.01||0.75||0.58|
|Share holders equity per share||1.2||1.04||1.01||0.75||0.58|
|Interest debt per share||1.05||1.02||0.88||0.73||0.71|
|Price to sales ratio||0||0||17.93M||0||165.34|
|EV to sales||0||0||21.83M||0||287.75|
|Enterprise value over EBITDA||-18.28||-13.39||2.19K||-6.17||-5.84|
|EV to operating cash flow||-22.26||-17.33||0||-7.21||-4.58|
|EV to free cash flow||-22.14||-17.18||0||-7.21||-4.57|
|Free cash flow yield||-0.05||-0.07||0||-0.2||-0.38|
|Debt to equity||0.86||0.95||0.81||0.87||1.03|
|Debt to assets||0.52||0.54||0.52||0.55||0.59|
|Net debt to EBITDA||-2.66||-2.27||391.73||-1.85||-2.48|
|Sales general and administrative to revenue||0||0||-3.75K||0||20.94|
|Research and developement to revenue||0||0||-6.01K||0||32|
|Intangibles to total assets||0||0||0||0||0|
|Capex to operating cash flow||0.01||0.01||0||0||0.01|
|Capex to revenue||0||0||0||0||-0.64|
|Capex to depreciation||-0.1||-0.14||0||0||-0.25|
|Stock based compensation to revenue||0||0||0||0||9.53|
|Return on tangible assets||-0.13||-0.13||0||-0.17||-0.13|
|Tangible asset value||0||0||0||0||0|
|Net current asset value||17.26M||16.77M||25.36M||19.71M||10.16M|
|Days sales outstanding||0||0||0||0||0|
|Days payables outstanding||0||0||0||0||0|
|Days of inventory on hand||0||0||0||0||0|
|Capex per share||0||0||0||0||0|
Frequently Asked Questions
What is Unity Biotechnology, Inc. stock symbol ?
Unity Biotechnology, Inc. is a US stock , located in Brisbane california of California and trading under the symbol UBX
Is Unity Biotechnology, Inc. buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $8. The lowest prediction is $8 and the highest is $8
What is UBX stock prediction ?
With a median analyst target price of $8, 2 stock analysts have made 2 forecasts in last 90 days. $8 is the lowest and $8 is the greatest projection.
What is Unity Biotechnology, Inc. stock quote today ?
Unity Biotechnology, Inc. stock price is $0.4096 today.
Is Unity Biotechnology, Inc. stock public?
Yes, Unity Biotechnology, Inc. is a publicly traded company.